Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea
Opinion
Weight reduction and results of liraglutide and lixisenatide in stoutness and type 2 diabetes mellitus
Author(s): Jung Min*
Obesity and Type 2 Diabetes Mellitus (T2DM) represent major global health challenges. Pharmacological interventions, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) including liraglutide and lixisenatide, have shown promise in both weight management and glycemic control. This study aims to systematically review and synthesize the impact of liraglutide and lixisenatide on weight reduction and metabolic outcomes in individuals with obesity and T2DM. A comprehensive search of electronic databases, including PubMed, MEDLINE, and Google Scholar, was conducted to identify relevant studies published between January 2000 and September 2023. Randomized controlled trials, observational studies, and systematic reviews assessing the effects of liraglutide and lixisenatide on weight reduction and metabolic parameters in individuals with obesity and T2DM were included.
A tot.. View More»
DOI:
10.35248/2155-6156.10001046
